Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS

Stock Information for Awakn Life Sciences

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Awakn Life Sciences

Awakn Life Sciences Announces Closing of Tranche of Private Placement
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange
Awakn Life Sciences Announces Conditional Approval of CSE Listing
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
Awakn Life Sciences Provides Corporate Update
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.